Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

[Serum A1-antitrypsin levels in prostate pathology].

Dokrunova AA, Sokolova OS.

Urologiia. 2012 Sep-Oct;(5):77-80. Russian.

PMID:
23342621
2.

Serum keratinocyte growth factor measurement in patients with prostate cancer.

Mehta PB, Robson CN, Neal DE, Leung HY.

J Urol. 2000 Dec;164(6):2151-5.

PMID:
11061946
3.

Serum adipocytokine levels in prostate cancer patients.

Arisan ED, Arisan S, Atis G, Palavan-Unsal N, Ergenekon E.

Urol Int. 2009;82(2):203-8. doi: 10.1159/000200801. Epub 2009 Mar 19.

PMID:
19322011
4.

Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.

Nagakawa O, Yamagishi T, Fujiuchi Y, Junicho A, Akashi T, Nagaike K, Fuse H.

Eur Urol. 2005 Oct;48(4):686-90.

PMID:
16005141
5.

[Activity of alpha 1-antitrypsin in blood of patients operated on for tumor and benign hyperplasia of the prostate].

Zietek Z, Iwan-Zietek I, Kotschy M, Tyloch F.

Pol Tyg Lek. 1996 Feb;51(6-9):77-8. Polish.

PMID:
8756736
6.

Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.

Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H.

J Urol. 1997 Dec;158(6):2188-92.

PMID:
9366341
7.

Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease.

España F, Martínez M, Sánchez-Cuenca J, Vera CD, Estellés A, Jiménez-Cruz JF.

Eur Urol. 1996;30(4):512-8.

PMID:
8977078
8.
10.

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.

J Urol. 2000 Jan;163(1):311-6.

PMID:
10604382
11.
12.

Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer.

Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL Jr, Vessella RL, Ralph D.

Urology. 1999 Jan;53(1):139-47.

PMID:
9886603
13.
14.

Progression of prostate cancer: diagnostic and prognostic utility of prostate-specific antigen, alpha2-macroglobulin, and their complexes.

Kanoh Y, Ohtani N, Ohara T, Mashiko T, Ohtani S, Egawa S, Baba S, Ohtani H.

Oncol Rep. 2001 May-Jun;8(3):515-9.

PMID:
11295072
15.

Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia.

Jung K, Lein M, Weiss S, Schnorr D, Henke W, Loening S.

Eur J Cancer. 1996 Apr;32A(4):627-30.

PMID:
8695265
16.

Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and breast cancer patients.

El-Akawi ZJ, Al-Hindawi FK, Bashir NA.

Neuro Endocrinol Lett. 2008 Aug;29(4):482-4.

PMID:
18766166
17.

Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.

Muecke R, Klotz T, Giedl J, Buentzel J, Kundt G, Kisters K, Prott FJ, Micke O.

Acta Oncol. 2009;48(3):452-6. doi: 10.1080/02841860802403721.

PMID:
18855158
18.

Immobilization of anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor prostatic diseases diagnosis.

de Melo-Júnior MR, Araújo-Filho JL, Lins CA, de Pontes-Filho NT, de Carvalho LB Jr.

Appl Biochem Biotechnol. 2010 Apr;160(8):2198-207. doi: 10.1007/s12010-009-8753-2. Epub 2009 Sep 2.

PMID:
19728168
19.

Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease.

Lakhey M, Ghimire R, Shrestha R, Bhatta AD.

Kathmandu Univ Med J (KUMJ). 2010 Apr-Jun;8(30):158-63.

PMID:
21209527
20.

Supplemental Content

Support Center